A Novel Liver Fibrosis Marker FIB‐5 Index Predicted Response to Cardiac Resynchronization Therapy and Prognostic Outcomes in Patients With Heart Failure

Abstract

ABSTRACTBackgroundThe fibrosis‐5 (FIB‐5) index is a noninvasive marker for assessing the progression of liver fibrosis and predictor in patients with heart failure (HF). This study investigated the association between the FIB‐5 index and response to cardiac resynchronization therapy (CRT) and evaluated its predictive value for prognosis.MethodsIn total, 203 patients who underwent CRT/CRT‐defibrillator (CRT‐D) implantation were retrospectively included. The FIB‐5 index was calculated using blood samples obtained before and after CRT/CRT‐D. Response to CRT was defined as a relative reduction in left ventricular end‐systolic volume of ≥15% 6 months after CRT/CRT‐D. We compared the prognosis after CRT/CRT‐D between the groups according to the FIB‐5 index.ResultsOne hundred and twenty‐three patients (61%) responded to CRT. The responder group demonstrated a significantly higher FIB‐5 index than the nonresponder group (−2.76 ± 3.85 vs. −4.67 ± 3.29, p < 0.001). Receiver‐operating characteristic analysis demonstrated that the area under the curve of the FIB‐5 index was 0.660 with a cutoff value of −4.00 for responders. In multivariate analysis, FIB‐5 index ≥ −4.00 was an independent predictor for CRT response (odds ratio: 3.665, p = 0.003), in addition to QRS duration ≥ 150 ms and echocardiographic dysynchrony. The FIB‐5 index increased significantly after 6 months in the responder group but not in the nonresponder group. The FIB‐5 index ≥ −4.00 group showed a significantly better prognosis for cardiac death, HF hospitalization, and composite endpoint than the FIB‐5 index < −4.00 group.ConclusionThe FIB‐5 index in addition to classical predictors may be a useful marker for predicting response to CRT.